PT-141 started life as an experimental melanocortin peptide, became linked with sexual arousal more or less by accident, and a pharmaceutical version eventually became an FDA approved medicine. That gives bremelanotide a much stronger human evidence base than most research peptides. The catch is that it is approved for one specific condition in one specific population, which is a long way from being an approved general "libido peptide".
What is PT-141?
PT-141 is the development code for bremelanotide, a synthetic ring shaped peptide of seven amino acids built on part of the natural hormone alpha melanocyte stimulating hormone, alpha-MSH 1. In the United States it is marketed as Vyleesi, a prescription autoinjector.
The FDA approved Vyleesi on 21 June 2019 Regulator approved indication 2. The approved use is the treatment of premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD): low sexual desire that causes marked distress or difficulty in the relationship and is not due to another medical or psychiatric condition, problems in the relationship, or the effects of a medicine or drug. "Acquired" means the problem developed in someone who previously had no difficulty with desire; "generalised" means it happens regardless of the situation or partner 3.
The label then sets out its limits in plain terms. Vyleesi is not indicated for HSDD in postmenopausal women or in men, and it is not indicated to enhance sexual performance. That is much narrower than the way PT-141 is usually sold online.
Where did PT-141 come from?
Bremelanotide came out of research into the melanocortin system, the same receptor family that alpha-MSH and Melanotan II act on. In a small pilot study published in 1996, three healthy men given Melanotan II for its tanning effect also had spontaneous erections lasting one to five hours after dosing, often preceded by stretching and yawning Human 4. A follow up trial in ten men with psychogenic erectile dysfunction found that eight developed clinically apparent erections on Melanotan II Human 5.
That unexpected effect turned the melanocortin system into a target for sexual function research, and PT-141 was developed along that line. Chemically the two peptides are almost identical: both are the same cyclic chain of seven amino acids, but Melanotan II ends in an amide group while bremelanotide ends in a free acid 4 3. Closely related, then, but not the same molecule, and with a very different regulatory history.
How does bremelanotide work?
Bremelanotide switches on melanocortin receptors. It is not selective: the label lists its order of potency as MC1R, then MC4R, MC3R, MC5R and MC2R, and says that at therapeutic doses binding to MC1R and MC4R is the most relevant Mechanistic. Neurons carrying MC4R are found in many parts of the brain, and this receptor has been linked with sexual behaviour, appetite and other functions. MC1R sits on the skin's pigment cells, which is why pigmentation turns up among the side effects.
The label is candid on one point: the mechanism by which Vyleesi improves HSDD in women is officially unknown. That is less strange than it sounds; a drug can work in trials before anyone has mapped every step between receptor and outcome.
Is PT-141 like Viagra?
Not really. Sildenafil and the other PDE5 inhibitors act mainly on blood flow in erectile tissue. Bremelanotide acts on melanocortin signalling in the nervous system, around the pathways that govern desire and arousal, which helps explain why its approved use concerns low desire rather than genital blood flow.
What did the phase 3 trials show?
This is where PT-141 parts company with most experimental peptides. The RECONNECT programme ran two identical phase 3 trials, studies 301 and 302, each randomised, double blind and placebo controlled, lasting 24 weeks, in premenopausal women with acquired, generalised HSDD Human 6. Of 1,267 women randomised, 1,247 formed the safety population and 1,202 the efficacy population. Their mean age was 39, and almost all were recruited at US sites. The drug was used as needed before anticipated sexual activity rather than every day.
There were two primary outcomes, both of which had to be met. The first was the desire domain of the Female Sexual Function Index, a two question score running from 1.2 to 6.0. The second was a single item from the Female Sexual Distress Scale asking how often the woman felt bothered by low sexual desire, scored from 0 (never) to 4 (always).
Both trials met both outcomes. On the desire score, the average rise was 0.5 points on bremelanotide against 0.2 on placebo in study 301, and 0.6 against 0.2 in study 302 3. Measured against placebo, the published gains were 0.30 and 0.42 points, or 0.35 when the two trials were combined. Distress about low desire fell by 0.37 and 0.29 points more than on placebo, 0.33 combined 6.
Those are genuine, replicated results, but they are small on the scales used. The FDA's own summary puts them in more familiar terms: about 25% of women on Vyleesi had a desire score increase of 1.2 points or more, against about 17% on placebo, and about 35% had a fall of at least one point in distress, against about 31% on placebo 2.
Dropout was also uneven. In the label, 40% of women on bremelanotide left the 24 week treatment period early in study 301, against 13% on placebo; in study 302 the figures were 39% and 25%. About 18% of women on the drug stopped because of side effects, against 2% on placebo.
Did women have more satisfying sexual events?
No, not significantly. The number of satisfying sexual events was a secondary outcome, and the label states there was no significant difference between bremelanotide and placebo. The drug moved questionnaire scores for desire and distress; it did not reliably change how often women had sex they found satisfying. That is why describing PT-141 as a straightforward "sex peptide" oversimplifies the evidence.
What happened over a longer period?
Women who finished the core trials could join a 52 week open label extension. Of 856 eligible women, 684 took part and 272 completed it Human 7. Those who stayed reported sustained improvement and no new safety signals were seen, but an open label group that has chosen to continue is self selected by design, and fewer than half finished.
Does PT-141 work in men?
Research in men exists, but it is not the evidence behind the approval. Early intranasal studies in healthy men and men with erectile dysfunction reported erections at the higher doses tested Human 8. The most cited male trial, a 2008 study of intranasal bremelanotide in 342 men who had not responded to sildenafil 9, was placed under a formal Expression of Concern by the Journal of Urology in January 2023, along with other papers by the same author, so BioRx does not treat it as reliable 10.
The intranasal route was dropped over blood pressure. In 2009 the developer, Palatin Technologies, reported that rises in blood pressure seen with the nasal spray were linked to high blood levels in a subset of patients, and that switching to injection under the skin appeared to address the blood pressure concerns the FDA had raised 11. No male indication was ever approved. The molecule clearly does something in men; that effect is simply not the use the regulator approved, and the trustworthy controlled evidence for it is thin.
What are the side effects?
Nausea is by far the biggest. In the pooled phase 3 trials it affected 40% of women on Vyleesi against 1% on placebo 3. It was most common after the first dose, 13% needed medicine to treat it, and 8% left the trials because of it. Other common effects, each more frequent than on placebo, were flushing (20%), injection site reactions (13%), headache (11%), vomiting (5%), and smaller rates of cough, fatigue, hot flush, tingling, dizziness and nasal congestion. That is a substantial burden for a medicine used as needed.
Blood pressure
Bremelanotide raises blood pressure and lowers heart rate for a few hours after each dose. In clinical studies the largest average increases were 6 mmHg systolic and 3 mmHg diastolic, peaking two to four hours after the injection, with heart rate falling by up to 5 beats per minute; readings usually returned to baseline within 12 hours. Vyleesi is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease, and not recommended for those at high risk of it. An approved peptide can still carry real cardiovascular cautions.
Pigmentation
Because bremelanotide also activates MC1R on pigment cells, it can darken patches of skin. In the phase 3 trials focal hyperpigmentation, affecting the face, gums and breasts, was reported in 1% of women and in no one on placebo. In a separate study where the drug was given daily for eight days, 38% developed it, and a further 14% developed new patches over eight more days. It was more likely in people with darker skin and did not always clear after stopping. This is the clearest link back to the Melanotan research the drug grew out of: the receptor system does more than one thing.
What limits does the label place on use?
Several, and they are part of what the approval means. The label says not to use more than one dose within 24 hours, because doses close together may add to the blood pressure effect, and advises against more than eight doses a month, because more frequent use raises the risk of pigmentation. Treatment should be stopped after eight weeks if the woman reports no improvement. Women who could become pregnant are advised to use effective contraception, and the drug should be stopped if pregnancy is suspected, because animal studies suggested possible harm to the fetus. Vyleesi can also slow stomach emptying, which may delay the absorption of some tablets, and it can sharply reduce blood levels of oral naltrexone.
Is PT-141 the same as Melanotan II?
No. They share a research history and, as described above, nearly the same structure, and both switch on several melanocortin receptors at once. Melanotan II was developed mainly around pigmentation, found to have sexual effects, and never approved anywhere; its controlled human record is three tiny studies from the 1990s. Bremelanotide was taken forward specifically for sexual function and became a licensed medicine in one country. Evidence for Vyleesi therefore should not be used to legitimise an unregulated Melanotan II product. Melanotan II explained covers the tanning peptide in detail.
| Compound | Mechanism | Half life | UK status | Evidence |
|---|---|---|---|---|
| Bremelanotide | Bremelanotide is a cyclic heptapeptide derived from alpha-MSH and is, chemically, the C-terminal deamidated (free acid) analogue of melanotan II. | Mean terminal half life approximately 2.7 hours (range 1.9-4.0 h) after subcutaneous injection, per the approved US labelling | No UK marketing authorisation. | High-quality evidence |
| Melanotan II | Melanotan II is a cyclic, lactam bridged truncation of alpha-MSH. | Not established in humans. | Not licensed by the MHRA for any indication. | Limited evidence |
Is PT-141 bought online the same as Vyleesi?
No. Approval applies to a specific product made to a specific quality standard, in a specific formulation and device, for a specific use. A grey market vial labelled "PT-141" has not been through the manufacturing controls, sterility testing or inspection that Vyleesi has, and nobody has checked that it contains what the label says. This is the principle BioRx applies across the library: evidence for a molecule does not validate an unknown product claiming to contain it.
UK and sporting position
Bremelanotide has no UK marketing authorisation; a search of the MHRA's product database returns no licensed product 12. There is no European authorisation either: bremelanotide does not appear in the European Medicines Agency's list of human medicines, which also records refused and withdrawn applications 13. Under the Human Medicines Regulations 2012 an unlicensed medicine cannot lawfully be sold or supplied for human use in the UK on the "research chemical" basis that PT-141 is usually marketed under.
For athletes, the 2026 WADA Prohibited List does not name bremelanotide or melanocortin agonists as a class 14. Its catch all S0 section covers substances with no current approval by any health regulator for human use; bremelanotide has US approval, so it falls outside that wording. An unregulated vial of unknown content is a separate risk, since it may contain something that is prohibited.
The BioRx conclusion
PT-141 is one of the few peptides widely discussed online that went all the way through large controlled trials and regulatory approval. Bremelanotide produced statistically significant, replicated improvements in sexual desire and in distress about low desire in premenopausal women with acquired, generalised HSDD, though the gains were small on the scales used and did not extend to more satisfying sexual events. That evidence has firm boundaries. It does not make bremelanotide an approved general libido enhancer, it does not establish benefit in men, and it does not make an unregulated product labelled "PT-141" equivalent to Vyleesi. It also carries a meaningful side effect profile, led by nausea and short lived rises in blood pressure. It is not an aphrodisiac in any general sense: PT-141 became a real medicine, for a much narrower purpose than the internet suggests.
Frequently asked questions
Is PT-141 legal in the UK?
It has no UK marketing authorisation and no European one. Supplying it for human use in the UK as a "research chemical" is not lawful under the Human Medicines Regulations 2012.
How well does bremelanotide work?
In two phase 3 trials it beat placebo on questionnaire measures of desire and of distress about low desire, but the differences were small, and it did not significantly increase satisfying sexual events. About 25% of women on the drug had a meaningful rise in desire score, against about 17% on placebo.
What is the most common side effect of PT-141?
Nausea, in about 40% of women in the trials against 1% on placebo, most often after the first dose. Flushing, injection site reactions and headache were also common, and blood pressure rises for a few hours after each dose.
Is PT-141 banned in sport?
The 2026 WADA Prohibited List does not name it, and its US approval places it outside the list's category for unapproved substances. An unregulated product of unknown content could still contain a prohibited substance.
References
Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.
- Molinoff PB et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction, Ann N Y Acad Sci 2003
- FDA news release, FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women, 21 June 2019
- FDA, Vyleesi prescribing information, 2019
- Dorr RT et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences.PubMed · View study in BioRx
- Wessells H et al. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. The Journal of Urology.PubMed · View study in BioRx
- Kingsberg SA et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology.PubMed · DOI · View study in BioRx
- Simon JA et al. (2019). Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology.PubMed · DOI · View study in BioRx
- Diamond LE et al. Intranasal PT-141 in healthy males and patients with erectile dysfunction, Int J Impot Res 2004
- Safarinejad MR, Hosseini SY (2008). Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. The Journal of Urology.PubMed · DOI · View study in BioRx
- Expression of Concern, J Urol 2023
- Palatin Technologies press release, 12 August 2009
- MHRA Products, search for bremelanotide
- EMA, medicines output report for human medicines, September 2026
- WADA, 2026 Prohibited List
